Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084329 | 0.82 | CNR1 (0.60) | SMN1; SMN2NPC1RAB9ACNR1ALDH1A1 | |
| SCHEMBL6083987 | 0.82 | CNR1 (0.60) | SMN1; SMN2NPC1RAB9ACNR1ALDH1A1 | |
| SCHEMBL6084495 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL6205464 | 0.81 | CNR1 (0.58) | SMN1; SMN2NPC1RAB9ACNR1ALDH1A1 | |
| SCHEMBL19701371 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL6083629 | 0.75 | RAB9A (0.53) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6083620 | 0.75 | RAB9A (0.53) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6085524 | 0.75 | RAB9A (0.53) | GRM5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL21490057 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL6084148 | 0.75 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | GRM5 5/4885SMN1; SMN2 332/4885NPC1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.